Natera Q4 revenue up 43% to $311M; net loss narrows; guides 2024 rev $1.32-1.35B

Natera, Inc.

2023-FY EPS reported -$3.78 revenue$1,082,571,000

Q4 revenue $311.1M (+43.2% YoY); product revenue up 44.3% to $307.3M.
Net loss per share Q4 ($0.65) vs ($1.37) prior year; full year loss ($3.78) vs ($5.57).
Gross margin Q4 51.4% vs 41.4% YoY; full year 45.5% vs 44.4%.
Oncology tests Q4 up 52.3% to 97,500; FY up 73.5% to 340,700.
FY2024 guidance: revenue $1.32-1.35B; gross margin 50-53%; net cash consumption $50-75M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Natera, Inc. reported fourth quarter and year ended December 31, 2023 results: revenue $311.1 million, net income ($0.65) per diluted share, EPS ($0.65) per diluted share.

Period: fourth quarter and year ended December 31, 2023
Revenue: $311.1 million
Net income: ($0.65) per diluted share
EPS: ($0.65) per diluted share
Result: reported results

Exact text from the filing

testing , today reported its financial results for the fourth quarter and year ended December 31, 2023. Recent Strategic and Financial Highlights ● Generated total revenues of $311.1 million in the fourth quarter of 2023, compared to $217.3 million in the fourth quarter of 2022, an increase of 43.2%. Product revenues grew 44.3% over the same period. ● Generated total

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Natera, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-028724

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.